ArticleThe Journal of clinical investigation2000
Treatment of murine lupus with cDNA encoding IFN-gammaR/Fc.
Article in The Journal of clinical investigation, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 158 citations in OpenAlex.
- Th1/17 polarization and potential treatment by an anti-interferon-γ DNA aptamer in Hunner-type interstitial cystitis.iScience · 2023Article
- IFN-γ, should not be ignored in SLE.Frontiers in immunology · 2022Review
- Type II but Not Type I IFN Signaling Is Indispensable for TLR7-Promoted Development of Autoreactive B Cells and Systemic Autoimmunity.Journal of immunology (Baltimore, Md. : 1950) · 2020Article
- Induction of Systemic Autoimmunity by a Xenobiotic Requires Endosomal TLR Trafficking and Signaling from the Late Endosome and Endolysosome but Not Type I IFN.Journal of immunology (Baltimore, Md. : 1950) · 2017Article
- Decreased ex vivo production of interferon-gamma is associated with severity and poor prognosis in patients with lupus.Arthritis research & therapy · 2017Article
- Spontaneous germinal centers and autoimmunity.Autoimmunity · 2017Review
- IFN-γ receptor and STAT1 signaling in B cells are central to spontaneous germinal center formation and autoimmunity.The Journal of experimental medicine · 2016Article
- The Role of the Transcription Factor Ets1 in Lupus and Other Autoimmune Diseases.Critical reviews in immunology · 2016Article
- Review
- Interferon-γ and systemic autoimmunity.Discovery medicine · 2013Review
- Critical role of transmethylation in TLR signaling and systemic lupus erythematosus.Clinical immunology (Orlando, Fla.) · 2013Article
- Definition of IFN-γ-related pathways critical for chemically-induced systemic autoimmunity.Journal of autoimmunity · 2012Article
- TLRs and IFNs: critical pieces of the autoimmunity puzzle.The Journal of clinical investigation · 2012Review
- Biological therapy in systemic lupus erythematosus.International journal of rheumatology · 2012Article
- Roles of pro- and anti-inflammatory cytokines in the pathogenesis of SLE.Journal of biomedicine & biotechnology · 2012Review
- Interferons in autoimmune and inflammatory diseases: regulation and roles.Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research · 2011Review
- Novel treatments for systemic lupus erythematosus.Therapeutic advances in musculoskeletal disease · 2011Article
- The multi-faceted influences of estrogen on lymphocytes: toward novel immuno-interventions strategies for autoimmunity management.Clinical reviews in allergy & immunology · 2011Review
- Murine models of systemic lupus erythematosus.Journal of biomedicine & biotechnology · 2011Review
- Th subset balance in lupus nephritis.Journal of biomedicine & biotechnology · 2011Review
Corrections and comments
- Commented on by
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
Abstract
IFN-gamma, a pleiotropic cytokine, is a key effector molecule in the pathogenesis of several autoimmune diseases, including lupus. Importantly, deletion of IFN-gamma or IFN-gammaR in several lupus-predisposed mouse strains resulted in significant disease reduction, suggesting the potential for therapeutic intervention. We evaluated whether intramuscular injections of plasmids with cDNA encoding IFN-gammaR/Fc can retard lupus development and progression in MRL-Fas(lpr) mice. Therapy significantly reduced serum levels of IFN-gamma, as well as disease manifestations (autoantibodies, lymphoid hyperplasia, glomerulonephritis, mortality), when treatment was initiated at the predisease stage, particularly when IFN-gammaR/Fc expression was enhanced by electroporation at the injection site. Remarkably, disease was arrested and even ameliorated when this treatment was initiated at an advanced stage. This therapy represents a rare example of disease reversal and makes application of this nonviral gene therapy in humans with lupus (and perhaps other autoimmune/inflammatory conditions) highly promising.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.